We are live on ! Find out more
EU

Emory University Portfolio holdings

AUM $267M
1-Year Est. Return 48.26%
This Fund
S&P 500
This Quarter Est. Return
+4.14%
1 Year Est. Return
+48.26%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$113M
AUM Growth
+$7.25M
Cap. Flow
+$6.12M
Cap. Flow %
5.4%
Top 10 Hldgs %
42.19%
Holding
57
New
16
Increased
8
Reduced
26
Closed
5

Top Buys

1
LOXO
Loxo Oncology, Inc
LOXO
+$1.89M
2
NXTM
NxStage Medical Inc.
NXTM
+$1.78M
3
ARAV
Aravive, Inc. Common Stock
ARAV
+$1.75M
4
ESPR
Esperion Therapeutics
ESPR
+$1.72M
5
TVTX icon
Travere Therapeutics
TVTX
+$1.65M

Top Sells

1
ARDX icon
Ardelyx
ARDX
+$2.4M
2
BLCM
Bellicum Pharmaceuticals, Inc.
BLCM
+$2.03M
3
LPLA icon
LPL Financial
LPLA
+$1.59M
4
TRN icon
Trinity Industries
TRN
+$1.54M
5
ZGNX
Zogenix, Inc.
ZGNX
+$1.34M

Sector Composition

1 Healthcare 43.85%
2 Financials 32.05%
3 Technology 5.46%
4 Energy 4.39%
5 Consumer Discretionary 4.29%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BRK.A icon
1
Berkshire Hathaway Class A
BRK.A
$1.06T
$29.8M 26.33%
117
– –
LOXO
2
DELISTED
Loxo Oncology, Inc
LOXO
$2.74M 2.42%
+34,143
New +$1.89M
ESPR
3
DELISTED
Esperion Therapeutics
ESPR
$2.16M 1.91%
+46,766
New +$1.72M
FOLD
4
DELISTED
Amicus Therapeutics
FOLD
$2.04M 1.8%
+202,357
New +$1.63M
SMC
5
Summit Midstream
SMC
$429M
$1.98M 1.75%
5,837
– –
AVXS
6
DELISTED
AveXis, Inc. Common Stock
AVXS
$1.87M 1.65%
22,750
-14,533
-39% -$1.09M
ONC
7
BeOne Medicines Ltd
ONC
$32.9B
$1.86M 1.64%
41,309
-16,345
-28% -$644K
NXTM
8
DELISTED
NxStage Medical Inc.
NXTM
$1.8M 1.59%
+71,954
New +$1.78M
TVTX icon
9
Travere Therapeutics
TVTX
$5.14B
$1.77M 1.56%
+91,108
New +$1.65M
BIVV
10
DELISTED
Bioverativ Inc. Common Stock
BIVV
$1.73M 1.53%
+28,817
New +$1.64M
ALNY icon
11
Alnylam Pharmaceuticals
ALNY
$37.8B
$1.72M 1.52%
+21,582
New +$1.38M
ZGNX
12
DELISTED
Zogenix, Inc.
ZGNX
$1.72M 1.52%
118,319
-106,501
-47% -$1.34M
ARAV
13
DELISTED
Aravive, Inc. Common Stock
ARAV
$1.71M 1.51%
+16,324
New +$1.75M
ACHN
14
DELISTED
Achillion Pharmaceuticals
ACHN
$1.71M 1.51%
372,327
-114,111
-23% -$459K
GHDX
15
DELISTED
Genomic Health, Inc.
GHDX
$1.71M 1.51%
52,459
-24,392
-32% -$773K
BFH icon
16
Bread Financial
BFH
$3.97B
$1.68M 1.49%
8,206
-682
-8% -$136K
LSXMK
17
DELISTED
Liberty Media Corporation Series C Liberty SiriusXM Common Stock
LSXMK
$1.68M 1.48%
52,729
-7,231
-12% -$217K
MS icon
18
Morgan Stanley
MS
$343B
$1.67M 1.48%
37,548
+1,766
+5% +$76.2K
CBRE icon
19
CBRE Group
CBRE
$42.1B
$1.66M 1.47%
45,689
-629
-1% -$21.9K
ALXN
20
DELISTED
Alexion Pharmaceuticals
ALXN
$1.66M 1.46%
13,607
-3,146
-19% -$366K
WBC
21
DELISTED
WABCO HOLDINGS INC.
WBC
$1.65M 1.46%
12,947
-1,025
-7% -$123K
ASND icon
22
Ascendis Pharma A/S
ASND
$17B
$1.65M 1.46%
59,455
-23,956
-29% -$633K
AWI icon
23
Armstrong World Industries
AWI
$6.86B
$1.65M 1.46%
35,831
-4,445
-11% -$199K
ESRX
24
DELISTED
Express Scripts Holding Company
ESRX
$1.63M 1.44%
25,600
+2,232
+10% +$140K
LEXEA
25
DELISTED
Liberty Expedia Holdings, Inc. Class A Common Stock
LEXEA
$1.63M 1.44%
30,162
-6,338
-17% -$320K
1
2 3

Similar funds

CFG
Cambridge Financial Group Columbus, Ohio $267M AUM 31.62% 1-Year Est. Return
PC
Packer & Co Cottesloe, Australia $267M AUM
ALC
Alexander Labrunerie & Co Columbia, Missouri $267M AUM 21.24% 1-Year Est. Return
TWM
TCFG Wealth Management Laguna Niguel, California $267M AUM 39.78% 1-Year Est. Return
IP
Indigo Partners Phoenix, Arizona $267M AUM 9% 1-Year Est. Return
SP
ShawSpring Partners Boston, Massachusetts $268M AUM 28.19% 1-Year Est. Return
EAIC
Empower Annuity Insurance Company Hartford, Connecticut $268M AUM 0.28% 1-Year Est. Return
STB
S&T Bank Indiana, Pennsylvania $268M AUM 39.92% 1-Year Est. Return

Emory University's Q2 2017 Portfolio in Review

As of Q2 2017, Emory University held 57 positions worth $113M, up 6.8% from $106M the previous quarter. Its ten largest holdings account for 42% of the portfolio.

Emory University deployed $6.12M of net new capital in Q2 2017, opening 16 new positions and adding to 8 existing holdings. Its largest new stake was Loxo Oncology, Inc: 34,143 shares worth $2.74M.

By sector, the portfolio is most concentrated in Healthcare at 44% of assets, up from 39% a quarter earlier, followed by Financials and Technology.

On the sell side, the largest reduction was Zogenix, Inc., an estimated $1.34M trimmed.

  • Emory University's largest Q2 2017 buy was Loxo Oncology, Inc: 34,143 shares worth $2.74M.
  • Emory University added most to Kinder Morgan in Q2 2017, an estimated $144K increase.
  • Emory University's biggest Q2 2017 reduction was Zogenix, Inc., cutting an estimated $1.34M.
  • Emory University fully exited Ardelyx in Q2 2017, selling an estimated $2.4M.
  • Emory University's ten largest holdings make up 42% of its $113M portfolio in Q2 2017.
  • Emory University opened 16 new positions and closed 5 in Q2 2017.
  • Emory University's portfolio value rose 6.8% quarter-over-quarter to $113M.

Based on Emory University's 13F filing for Q2 2017, filed 10 Aug 2017.